数据中心
龙虎榜
大单追踪
资金流向
业绩预告
新股申购
行情中心
沪深市场
香港市场
美国市场
全球市场
行业风云
全球市场
向上 向下

   ACET
-- -- --

今开：-- 昨收：-- 最高：-- 最低：--
成交量：--万手 市盈率：-- 总市值($)：-- 换手率：--
加入自选股

首页概览 公司概况 财务分析 高管介绍 股本结构 公司新闻

董事介绍

注：董事持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Andrew Sinclair 男 Director 49 9.70万美元 13.86 2021-03-15
Jeffrey Chodakewitz 男 Director 66 6.89万美元 13.16 2021-03-15
Bastiano Sanna 男 Director 46 23.32万美元 未持股 2021-03-15
Aya Jakobovits 女 Director 68 3.58万美元 未持股 2021-03-15
Carl L. Gordon -- Director 56 未披露 未持股 2021-03-15
Carl L. Gordon 男 Director 56 2.37万美元 未持股 2021-03-15
Chen Schor 男 Director, President and Chief Executive Officer 53 146.57万美元 386.35 2021-03-15
Steve Dubin 男 Director 67 8.21万美元 13.66 2021-03-15

高管介绍

注：高管持股数取自最新公司公告

姓名 性别 职位 年龄 薪酬 持股数(万股) 截止日期
Don Healey 男 Chief Technology Officer 59 未披露 未持股 2021-03-15
Stewart Abbot 男 Chief Scientific and Operating Officer 54 未披露 未持股 2021-03-15
Francesco Galimi 男 Chief Medical Officer 53 184.78万美元 未持股 2021-03-15
Carrie Krehlik 女 Chief Human Resource Officer 53 未披露 未持股 2021-03-15
Nick Harvey 男 Chief Financial Officer 60 152.34万美元 96.17 2021-03-15
Chen Schor 男 Director, President and Chief Executive Officer 48 146.57万美元 386.35 2021-03-15

董事简历

中英对照 |  中文 |  英文
Andrew Sinclair

Andrew Sinclair自2016年7月起担任董事会非执行董事。根据我们于2016年6月与Abingworth签订的关系协议，Sinclair博士被Abingworth BioVentures VI，LP或Abingworth任命为我们的董事会成员。尽管该协议在2020年私募结束时自动终止，但辛克莱博士继续担任非执行董事。2008年以来，他曾一直担任Abingworth公司（生命科学投资集团）的多种职务，在那里他目前担任合伙人兼投资组合经理（2015年12月以来）。他自2018年12月起担任Soleno Therapeutics的董事会成员，自2019年11月起担任Sierra Therapeutics的董事会成员。Sinclair博士是英格兰和威尔士特许会计师协会（Institute of Chartered Accountants in England and Wales）的成员，并在诺维奇BBSRC植物科学研究所（Institute of Plant Science）获得化学与遗传工程博士学位，并获得理学学士学位。毕业于伦敦国王学院微生物学专业。


Andrew Sinclair has served as a Non-Executive Director on our Board of Directors since July 2016. Dr. Sinclair was designated for appointment to our Board of Directors by Abingworth Bioventures VI, LP, or Abingworth, pursuant to a relationship agreement that we entered into with Abingworth in June 2016. Although such agreement automatically terminated on the closing of the 2020 Private Placement, Dr. Sinclair continues to serve as a Non-Executive Director. Since 2008 Dr. Sinclair has held various positions at Abingworth LLP, a life sciences investment group, where he is currently a Partner and Portfolio Manager, a role he has held since December 2015. He has served as a member of the boards of directors of Soleno Therapeutics since December 2018 and Sierra Therapeutics since November 2019. Dr. Sinclair is a member of the Institute of Chartered Accountants in England and Wales and received a Ph.D. in chemistry and genetic engineering at the BBSRC Institute of Plant Science, Norwich, and a B.Sc. in microbiology from King’s College London.
Andrew Sinclair自2016年7月起担任董事会非执行董事。根据我们于2016年6月与Abingworth签订的关系协议，Sinclair博士被Abingworth BioVentures VI，LP或Abingworth任命为我们的董事会成员。尽管该协议在2020年私募结束时自动终止，但辛克莱博士继续担任非执行董事。2008年以来，他曾一直担任Abingworth公司（生命科学投资集团）的多种职务，在那里他目前担任合伙人兼投资组合经理（2015年12月以来）。他自2018年12月起担任Soleno Therapeutics的董事会成员，自2019年11月起担任Sierra Therapeutics的董事会成员。Sinclair博士是英格兰和威尔士特许会计师协会（Institute of Chartered Accountants in England and Wales）的成员，并在诺维奇BBSRC植物科学研究所（Institute of Plant Science）获得化学与遗传工程博士学位，并获得理学学士学位。毕业于伦敦国王学院微生物学专业。
Andrew Sinclair has served as a Non-Executive Director on our Board of Directors since July 2016. Dr. Sinclair was designated for appointment to our Board of Directors by Abingworth Bioventures VI, LP, or Abingworth, pursuant to a relationship agreement that we entered into with Abingworth in June 2016. Although such agreement automatically terminated on the closing of the 2020 Private Placement, Dr. Sinclair continues to serve as a Non-Executive Director. Since 2008 Dr. Sinclair has held various positions at Abingworth LLP, a life sciences investment group, where he is currently a Partner and Portfolio Manager, a role he has held since December 2015. He has served as a member of the boards of directors of Soleno Therapeutics since December 2018 and Sierra Therapeutics since November 2019. Dr. Sinclair is a member of the Institute of Chartered Accountants in England and Wales and received a Ph.D. in chemistry and genetic engineering at the BBSRC Institute of Plant Science, Norwich, and a B.Sc. in microbiology from King’s College London.
Jeffrey Chodakewitz

Jeffrey Chodakewitz自2018年8月以来一直担任我们的董事会成员。从2018年4月到2019年3月，Chodakewitz博士担任Vertex Pharmaceuticals临床医学和外部创新执行Vice President。在此之前，Chodakewitz博士于2014年1月至2018年4月在Vertex担任首席医疗官兼全球药物开发和医疗事务执行Vice President，并担任Vertex执行委员会成员。在2014年1月加入Vertex之前，他在默克公司（Merck&Co.）工作了20多年，从2013年8月到2013年12月，他在该公司担任多个职位，包括传染病和疫苗全球开发主管，全球科学战略传染病高级副总裁，呼吸和免疫学从2013年1月至2013年8月，高级副总裁晚期发展从2011年3月至2013年1月。Chodakewitz博士是the National Board of Medical Examiners和the American Board of Internal Medicine（内科和传染病）的文凭。Chodakewitz博士目前在TetraphasePharmaceuticals，Inc.和Freeline Therapeutics Ltd.的董事会任职。他以优异成绩获得耶鲁大学生物化学学士学位和耶鲁大学医学院医学博士学位。


Jeffrey Chodakewitz has served as a member of Board of Directors since April 2021. Dr. Chodakewitz has served as an advisory partner for Ascenta Capital, a life sciences investment firm, since December 2022. He previoly served as a senior advisor to Blackstone Life Sciences, a life sciences private equity firm from March 2019 to January 2022. From April 2018 through March 2019, he served as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals, Inc., or Vertex. Prior to that role,Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs at Vertex from January 2014 to April 2018 and was a member of the Vertex Executive Committee. Prior to Vertex, Dr. Chodakewitz spent over 20 years at Merck & Co. serving in several positions, including leadership roles as Head of Infectio Diseases and Vaccines Global Development, Senior Vice President of Global Scientific Strategy (infectio disease, respiratory & immunology), Vice President of Early Stage Development and Senior Vice President of Late Stage Development. Dr. Chodakewitz currently serves on the boards of directors of Adicet Bio, Inc. (NASDAQ: ACET) and Schrdinger, Inc. (NASDAQ:SDGR). Dr. Chodakewitz previoly served on the board of directors of Freeline Therapeutics Holdings plc. Dr. Chodakewitz received a B.S. in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine.
Jeffrey Chodakewitz自2018年8月以来一直担任我们的董事会成员。从2018年4月到2019年3月，Chodakewitz博士担任Vertex Pharmaceuticals临床医学和外部创新执行Vice President。在此之前，Chodakewitz博士于2014年1月至2018年4月在Vertex担任首席医疗官兼全球药物开发和医疗事务执行Vice President，并担任Vertex执行委员会成员。在2014年1月加入Vertex之前，他在默克公司（Merck&Co.）工作了20多年，从2013年8月到2013年12月，他在该公司担任多个职位，包括传染病和疫苗全球开发主管，全球科学战略传染病高级副总裁，呼吸和免疫学从2013年1月至2013年8月，高级副总裁晚期发展从2011年3月至2013年1月。Chodakewitz博士是the National Board of Medical Examiners和the American Board of Internal Medicine（内科和传染病）的文凭。Chodakewitz博士目前在TetraphasePharmaceuticals，Inc.和Freeline Therapeutics Ltd.的董事会任职。他以优异成绩获得耶鲁大学生物化学学士学位和耶鲁大学医学院医学博士学位。
Jeffrey Chodakewitz has served as a member of Board of Directors since April 2021. Dr. Chodakewitz has served as an advisory partner for Ascenta Capital, a life sciences investment firm, since December 2022. He previoly served as a senior advisor to Blackstone Life Sciences, a life sciences private equity firm from March 2019 to January 2022. From April 2018 through March 2019, he served as Executive Vice President, Clinical Medicine and External Innovation, at Vertex Pharmaceuticals, Inc., or Vertex. Prior to that role,Dr. Chodakewitz held the roles of Chief Medical Officer and Executive Vice President, Global Medicines Development and Medical Affairs at Vertex from January 2014 to April 2018 and was a member of the Vertex Executive Committee. Prior to Vertex, Dr. Chodakewitz spent over 20 years at Merck & Co. serving in several positions, including leadership roles as Head of Infectio Diseases and Vaccines Global Development, Senior Vice President of Global Scientific Strategy (infectio disease, respiratory & immunology), Vice President of Early Stage Development and Senior Vice President of Late Stage Development. Dr. Chodakewitz currently serves on the boards of directors of Adicet Bio, Inc. (NASDAQ: ACET) and Schrdinger, Inc. (NASDAQ:SDGR). Dr. Chodakewitz previoly served on the board of directors of Freeline Therapeutics Holdings plc. Dr. Chodakewitz received a B.S. in Biochemistry cum laude from Yale University and an M.D. from the Yale University School of Medicine.
Bastiano Sanna

Bastiano Sanna自2020年2月起担任Vertex Pharmaceuticals Incorporated的执行副总裁、细胞和基因治疗主管。2019年10月至2020年2月，他担任Semma Therapeutics，Inc.的总裁。Semma Therapeutics，Inc.是Vertex于2019年10月收购的一家私营生物技术公司。收购前，Sanna博士于2018年5月至2019年10月担任Semma首席执行官兼总裁。Sanna博士于2016年5月至2018年4月担任品红治疗公司首席运营官。2014年至2016年，他在诺华细胞和基因治疗部门的领导团队中担任干细胞移植和早期项目的全球项目负责人。2010年至2014年，Sanna博士担任诺华生物医药研究院战略规划和投资组合管理全球主管。Sanna博士自2020年12月起担任生物技术公司Adicet Bio，Inc.董事会成员。桑纳博士获得萨萨里大学生物技术博士学位。


Bastiano Sanna,is Vertex Pharmaceuticals Incorporated Executive Vice President, Chief of Cell and Genetic Therapies, a position he has held since February 2020. From October 2019 to February 2020, he was President of Semma Therapeutics, Inc., a private biotechnology company that Vertex acquired in October 2019. Prior to the acquisition, Dr. Sanna was the Chief Executive Officer and President of Semma from May 2018 until October 2019. Dr. Sanna was Chief Operating Officer at Magenta Therapeutics from May 2016 through April 2018. He served on the leadership team of the Novartis Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs from 2014 through 2016. Dr. Sanna served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research from 2010 through 2014. Dr. Sanna has served as a member of the Board of Directors of Adicet Bio, Inc., a biotechnology company since December 2020. Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.
Bastiano Sanna自2020年2月起担任Vertex Pharmaceuticals Incorporated的执行副总裁、细胞和基因治疗主管。2019年10月至2020年2月，他担任Semma Therapeutics，Inc.的总裁。Semma Therapeutics，Inc.是Vertex于2019年10月收购的一家私营生物技术公司。收购前，Sanna博士于2018年5月至2019年10月担任Semma首席执行官兼总裁。Sanna博士于2016年5月至2018年4月担任品红治疗公司首席运营官。2014年至2016年，他在诺华细胞和基因治疗部门的领导团队中担任干细胞移植和早期项目的全球项目负责人。2010年至2014年，Sanna博士担任诺华生物医药研究院战略规划和投资组合管理全球主管。Sanna博士自2020年12月起担任生物技术公司Adicet Bio，Inc.董事会成员。桑纳博士获得萨萨里大学生物技术博士学位。
Bastiano Sanna,is Vertex Pharmaceuticals Incorporated Executive Vice President, Chief of Cell and Genetic Therapies, a position he has held since February 2020. From October 2019 to February 2020, he was President of Semma Therapeutics, Inc., a private biotechnology company that Vertex acquired in October 2019. Prior to the acquisition, Dr. Sanna was the Chief Executive Officer and President of Semma from May 2018 until October 2019. Dr. Sanna was Chief Operating Officer at Magenta Therapeutics from May 2016 through April 2018. He served on the leadership team of the Novartis Cell and Gene Therapy Unit as the Global Program Head of Stem Cell Transplant and early programs from 2014 through 2016. Dr. Sanna served as Global Head of Strategic Planning and Portfolio Management at the Novartis Institutes for BioMedical Research from 2010 through 2014. Dr. Sanna has served as a member of the Board of Directors of Adicet Bio, Inc., a biotechnology company since December 2020. Dr. Sanna received a Ph.D. in Biotechnology from the University of Sassari.
Aya Jakobovits

Aya Jakobovits自2020年9月RestorBio和前ADicet合并完成以来一直担任我们的董事会成员，此前自2014年11月以来一直担任前ADicet的董事会成员。Jakobovits博士创立了前ADICET，并从其成立至2018年2月担任总裁兼首席执行官。从2018年2月至2019年2月，Jakobovits博士担任前ADICET的高级战略顾问。在创办Former Adicet之前，Jakobovits博士于2011年至2016年担任OrbiMed Advisors的风险合伙人。从2010年9月到2013年12月，她曾担任Kite Pharma公司的总裁兼创始首席执行官。从2007年12月到2010年6月，她曾担任Agensys公司（Astellas Pharma公司的附属公司）的执行Vice President、研究与开发主管。在Agensys公司被Astellas公司收购之前，1999年1月至2007年12月，她曾担任Agensys公司的技术和企业发展高级副总裁，和首席科学官，并领导其研究、开发、临床和企业发展业务。加入Agensys之前，Jakobovits从1996年到1999年担任Abgenix Inc.（1996年从Cell Genesys，Inc.分拆出来，基于在她领导下开发的Xenomouse&174；技术）发现研究主管和首席科学家。她于1989年加入Cell Genesys公司，并最终担任分子免疫学董事。Jakobovits博士目前在Dorian Therapeutics公司、Yeda研究与开发有限公司和加州大学洛杉矶分校技术开发公司的董事会任职。Jakobovits博士此前曾于2013年至2015年担任CCAM Therapeutics Ltd.的董事会成员，并于2015年至2019年担任癌症基因治疗联盟的董事会成员。Jakobovits博士获得了理学学士学位。Hebrew University of Jerusalem理学硕士学位。在以色列魏茨曼科学研究所获得化学博士学位和生命科学博士学位，是加利福尼亚大学旧金山分校和Genentech，Inc.的博士后


Aya Jakobovits has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as a member of the board of directors of Former Adicet since November 2014. Dr. Jakobovits founded Former Adicet and served as President and Chief Executive Officer from its incorporation until February 2018. From February 2018 until February 2019 Dr. Jakobovits served as a senior strategic advisor to Former Adicet. Prior to starting Former Adicet, Dr. Jakobovits served as a Venture Partner with OrbiMed Advisors from 2011 to 2016. From September 2010 to December 2013 she served as President and Founding Chief Executive Officer of Kite Pharma Inc. From December 2007 to June 2010 she served as Executive Vice President, Head of Research and Development at Agensys Inc., an affiliate of Astellas Pharma, Inc. Before Agensys’ acquisition by Astellas, she served as Agensys’ Senior Vice President, Technology and Corporate Development and Chief Scientific Officer and led its research, development, clinical and corporate development operations from January 1999 to December 2007. Before Agensys, from 1996 to 1999 Dr. Jakobovits served as Director, Discovery Research and Principal Scientist at Abgenix Inc. which was spun out of Cell Genesys, Inc. in 1996 based on the XenoMouse® technology developed under her leadership. She joined Cell Genesys in 1989 and served ultimately as Director, Molecular Immunology. Dr. Jakobovits currently serves on the boards of directors of Dorian Therapeutics Inc., Yeda Research and Development Co. Ltd., and the UCLA Technology Development Corporation. Dr. Jakobovits previously served on the boards of directors of cCAM therapeutics Ltd. from 2013 to 2015 and the Alliance for Cancer Gene Therapy from 2015 to 2019. Dr. Jakobovits received her B.Sc. from the Hebrew University of Jerusalem, her M.Sc. in Chemistry and Ph.D. in Life Sciences from the Weizmann Institute of Sciences, Israel, and was a postdoctoral fellow at University of California, San Francisco and at Genentech, Inc.
Aya Jakobovits自2020年9月RestorBio和前ADicet合并完成以来一直担任我们的董事会成员，此前自2014年11月以来一直担任前ADicet的董事会成员。Jakobovits博士创立了前ADICET，并从其成立至2018年2月担任总裁兼首席执行官。从2018年2月至2019年2月，Jakobovits博士担任前ADICET的高级战略顾问。在创办Former Adicet之前，Jakobovits博士于2011年至2016年担任OrbiMed Advisors的风险合伙人。从2010年9月到2013年12月，她曾担任Kite Pharma公司的总裁兼创始首席执行官。从2007年12月到2010年6月，她曾担任Agensys公司（Astellas Pharma公司的附属公司）的执行Vice President、研究与开发主管。在Agensys公司被Astellas公司收购之前，1999年1月至2007年12月，她曾担任Agensys公司的技术和企业发展高级副总裁，和首席科学官，并领导其研究、开发、临床和企业发展业务。加入Agensys之前，Jakobovits从1996年到1999年担任Abgenix Inc.（1996年从Cell Genesys，Inc.分拆出来，基于在她领导下开发的Xenomouse&174；技术）发现研究主管和首席科学家。她于1989年加入Cell Genesys公司，并最终担任分子免疫学董事。Jakobovits博士目前在Dorian Therapeutics公司、Yeda研究与开发有限公司和加州大学洛杉矶分校技术开发公司的董事会任职。Jakobovits博士此前曾于2013年至2015年担任CCAM Therapeutics Ltd.的董事会成员，并于2015年至2019年担任癌症基因治疗联盟的董事会成员。Jakobovits博士获得了理学学士学位。Hebrew University of Jerusalem理学硕士学位。在以色列魏茨曼科学研究所获得化学博士学位和生命科学博士学位，是加利福尼亚大学旧金山分校和Genentech，Inc.的博士后
Aya Jakobovits has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as a member of the board of directors of Former Adicet since November 2014. Dr. Jakobovits founded Former Adicet and served as President and Chief Executive Officer from its incorporation until February 2018. From February 2018 until February 2019 Dr. Jakobovits served as a senior strategic advisor to Former Adicet. Prior to starting Former Adicet, Dr. Jakobovits served as a Venture Partner with OrbiMed Advisors from 2011 to 2016. From September 2010 to December 2013 she served as President and Founding Chief Executive Officer of Kite Pharma Inc. From December 2007 to June 2010 she served as Executive Vice President, Head of Research and Development at Agensys Inc., an affiliate of Astellas Pharma, Inc. Before Agensys’ acquisition by Astellas, she served as Agensys’ Senior Vice President, Technology and Corporate Development and Chief Scientific Officer and led its research, development, clinical and corporate development operations from January 1999 to December 2007. Before Agensys, from 1996 to 1999 Dr. Jakobovits served as Director, Discovery Research and Principal Scientist at Abgenix Inc. which was spun out of Cell Genesys, Inc. in 1996 based on the XenoMouse® technology developed under her leadership. She joined Cell Genesys in 1989 and served ultimately as Director, Molecular Immunology. Dr. Jakobovits currently serves on the boards of directors of Dorian Therapeutics Inc., Yeda Research and Development Co. Ltd., and the UCLA Technology Development Corporation. Dr. Jakobovits previously served on the boards of directors of cCAM therapeutics Ltd. from 2013 to 2015 and the Alliance for Cancer Gene Therapy from 2015 to 2019. Dr. Jakobovits received her B.Sc. from the Hebrew University of Jerusalem, her M.Sc. in Chemistry and Ph.D. in Life Sciences from the Weizmann Institute of Sciences, Israel, and was a postdoctoral fellow at University of California, San Francisco and at Genentech, Inc.
Carl L. Gordon

CarlL.Gordon自2020年9月RestorBio与前ADICET合并完成以来一直担任我们的董事会成员，此前自2015年8月以来一直担任前ADICET的董事会成员。Gordon博士是OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管。Gordon博士目前在KerosTherapeutics，Inc.、ORICPharmaceuticals，Inc.和几家私营公司的董事会任职。Gordon博士曾在IntelliaTherapeutics，Inc.ARMOBioSciences，Inc.Acceleron PharmaInc.的Alector，Inc.（X4Pharmaceuticals，Inc.前身为Arsanis，Inc.）的董事会任职。SelectaBiosciences，Inc.、PassageBio，Inc.和Springworks Therapeutics Inc.。Gordon博士在哈佛学院（Harvard College）获得化学学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得分子生物学博士学位，并且是洛克菲勒大学（Rockefeller University）的研究员。


Carl L. Gordon has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as a member of the board of directors of Former Adicet since August 2015. Dr. Gordon is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Keros Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and several private companies. Dr. Gordon previously served on the boards of directors of Alector, Inc., X4 Pharmaceuticals, Inc. formerly Arsanis, Inc., Acceleron Pharma Inc., ARMO Biosciences, Inc., Intellia Therapeutics, Inc. Selecta Biosciences, Inc., Passage Bio, Inc., and SpringWorks Therapeutics Inc. Dr. Gordon received a B.A. in Chemistry from Harvard College and a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.
CarlL.Gordon自2020年9月RestorBio与前ADICET合并完成以来一直担任我们的董事会成员，此前自2015年8月以来一直担任前ADICET的董事会成员。Gordon博士是OrbiMed Advisors LLC（一家投资公司）的创始成员、管理合伙人和全球私募股权联席主管。Gordon博士目前在KerosTherapeutics，Inc.、ORICPharmaceuticals，Inc.和几家私营公司的董事会任职。Gordon博士曾在IntelliaTherapeutics，Inc.ARMOBioSciences，Inc.Acceleron PharmaInc.的Alector，Inc.（X4Pharmaceuticals，Inc.前身为Arsanis，Inc.）的董事会任职。SelectaBiosciences，Inc.、PassageBio，Inc.和Springworks Therapeutics Inc.。Gordon博士在哈佛学院（Harvard College）获得化学学士学位，在麻省理工学院（Massachusetts Institute of Technology）获得分子生物学博士学位，并且是洛克菲勒大学（Rockefeller University）的研究员。
Carl L. Gordon has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as a member of the board of directors of Former Adicet since August 2015. Dr. Gordon is a founding member, Managing Partner, and Co-Head of Global Private Equity at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Keros Therapeutics, Inc., ORIC Pharmaceuticals, Inc., and several private companies. Dr. Gordon previously served on the boards of directors of Alector, Inc., X4 Pharmaceuticals, Inc. formerly Arsanis, Inc., Acceleron Pharma Inc., ARMO Biosciences, Inc., Intellia Therapeutics, Inc. Selecta Biosciences, Inc., Passage Bio, Inc., and SpringWorks Therapeutics Inc. Dr. Gordon received a B.A. in Chemistry from Harvard College and a Ph.D. in Molecular Biology from the Massachusetts Institute of Technology and was a Fellow at The Rockefeller University.
Carl L. Gordon

Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。


Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
Carl L. Gordon，自1998年起担任OrbiMed创始成员、管理合伙人和全球私募股权联席主管。Gordon博士自2015年起担任Adicet Bio, Inc.（纳斯达克1：KNTE）董事会成员、2022年12月起担任Arrivent Biopharma，Inc.（纳斯达克：AVBP）董事会成员、2015年9月起担任Compass Therapeutics, Inc.（纳斯达克：CMPX）、2020年3月起担任Keros Therapeutics, Inc.（纳斯达克：KROS）、2019年12月起担任KinnateTERM10 Biopharma，Inc.（纳斯达克：TERM12）、Terns Pharmaceuticals, Inc.（纳斯达克：TERN）自10月Gordon博士此前曾于2013年10月至2019年6月在Alector Inc.（纳斯达克：ALEC）董事会任职，Arsanis，Inc.（与ORIC制药 Pharmaceuticals，Inc.合并）于2013年1月至2019年3月、Gemini Therapeutics, Inc.（与Disc Medicine，Inc.合并）于2016年4月至2022年12月、TERM4，Inc.（与Disc Medicine，Inc.合并）于2015年11月至2021年11月、Passage Bio Inc.（纳斯达克：ORIC）于2018年9月至2020年2月、Prevail Therapeutics Inc.TERM10（被Eli Lilly and Company收购）于2017年10月至2018年6月至2024年2月任职的Theseus Pharmaceuticals, Inc.（纳斯达克：THRX）和2017年5月至2020年11月任职的Turning Point Therapeutics, Inc.（被百时美施贵宝公司收购）。Gordon博士分别获得哈佛大学化学学士学位、麻省理工学院分子生物学博士学位和洛克菲勒大学博士后学位。
Carl L. Gordon has served as a member of Adarx Pharmaceuticals, Inc.'s board of directors since January 2020. Dr. Gordon is a Managing Partner at OrbiMed Advisors LLC, an investment firm. Dr. Gordon currently serves on the boards of directors of Compass Therapeutics Inc., a public biopharmaceutical company, since September 2015, BlossomHill Therapeutics, Inc., a public biopharmaceutical company, since February 2021, Scribe Therapeutics Inc., a public biopharmaceutical company, since March 2021, Electra Therapeutics, Inc., a public biopharmaceutical company, since March 2019, and Lomond Therapeutics Holdings, Inc. since March 2021, as well as several private companies. Dr. Gordon previously served on the boards of directors of several publicly traded companies, including Adicet Bio, Inc. from August 2015 to April 2025, ArriVent Biopharma, Inc. from December 2022 to June 2025, Gemini Therapeutics, Inc. (which merged with Disc Medicine, Inc.) from April 2016 to December 2022, Keros Therapeutics, Inc. from March 2020 to March 2026, Kinnate Biopharma, Inc. from December 2019 to April 2024, MBX Biosciences, Inc. from July 2020 to June 2025, ORIC Pharmaceuticals, Inc. from November 2015 to November 2021, Terns Pharmaceuticals, Inc. from October 2018 to February 2025, and Theseus Pharmaceuticals, Inc. from June 2018 to February 2024. Dr. Gordon received his B.A. in Chemistry from Harvard College, his Ph.D. in Molecular Biology from the Massachusetts Institute of Technology, and was a Fellow at The Rockefeller University.
Chen Schor

Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。


Chen Schor has served as a member of Karyopharm Therapeutics Inc.'s Board since 2020. Mr. Schor has served as the President, Chief Executive Officer and Director of Adicet Bio, Inc. ("Adicet Bio"), a public biotechnology company, since 2020. He held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and on the board of directors of Alliance for Cancer Gene Therapy, a non for profit organization committed to advancing new cancer cell and gene therapies, since December 2021. Mr. Schor has also served as chair of the board of directors of Koslapp Therapeutics, Inc., a private company, since June 2025. He previously served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant.
Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。
Chen Schor has served as a member of Karyopharm Therapeutics Inc.'s Board since 2020. Mr. Schor has served as the President, Chief Executive Officer and Director of Adicet Bio, Inc. ("Adicet Bio"), a public biotechnology company, since 2020. He held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and on the board of directors of Alliance for Cancer Gene Therapy, a non for profit organization committed to advancing new cancer cell and gene therapies, since December 2021. Mr. Schor has also served as chair of the board of directors of Koslapp Therapeutics, Inc., a private company, since June 2025. He previously served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant.
Steve Dubin

Steve Dubin于2014年1月担任Enzymotec Ltd.公司董事会主席，之前是副主席，于2013年4月被任命为董事。2011年11月，他担任SDA Ventures LLC公司高管，该公司主要针对健康和保健产品公司，从事协助新兴公司和中间市场公司处理包括商业开发、兼并、客户关系、发展策略及公司财政等问题。在SDA Ventures公司工作前，他担任位于纽约、芝加哥旧金山的全球私募股权投资公司Paine & Partners, LLC的资深顾问，主要从事人类和动物食品保健产品行业发现投资机会进行投资。2006年直到2011年2月被Royal DSM N.V。公司收购，他担任Martek Biosciences Corporation公司CEO。之后于2011年2月至2011年10月担任DSM的营养油类产品分部总裁，并于2011年11月至2012年10月担任DSM公司保健产品高级顾问。在1992年加入Martek公司之后他担任多个职位，包括首席财务官、财务主管、秘书、法律总顾问和商业开发高级副总裁等，他于2003年至2006年期间是Martek公司总裁。2000年至2003年，他联合创立并联合管理马里兰州一家天使投资俱乐部（angel-investing club），并于2001年至2002年一段时间担任Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C。公司法律顾问。他目前担任多家私人持有公司董事会成员，包括在NeurExpand Brain Center LLC公司即之前的The Brain Center, LLC公司担任董事会副主席、在MyCell Technologies公司及其子公司Oceans Omega LLC, and Alcresta, Inc.里担任董事会成员。2011年至2012年，他是Scerene Healthcare, Inc.董事会成员。他在马里兰大学（University of Maryland）获得会计学学士学位，在乔治华盛顿大学国家法律中心（National Law Center at George Washington University）获得法学博士学位。他是注册会计师并是Maryland Bar的成员。


Steve Dubin has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020. Since November 2011 Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health & wellness and nutritional products markets, on matters including corporate development, business acquisition, customer relations, growth strategies and corporate finance. In connection with SDA Ventures LLC, Mr. Dubin acts as a Senior Advisor to Paine Schwartz Partners, LLC, a global private equity investment firm located in New York, and San Mateo, for the purpose of identifying and executing investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011 Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He later served as President of DSM’s Nutritional Lipids Division from February 2011 through October 2011 and as a Senior Advisor to DSM Nutritional Products from November 2011 through October 2012. After joining Martek in 1992 and serving in various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, he served as President of Martek from 2003 to 2006. Mr. Dubin currently serves as a member of the board of directors of privately held companies Alcresta Therapeutics, Inc., The UCAN Company, Triton Algae Innovations, Ltd. and Phytolon LTD. From January 2014 to January 2018 Mr. Dubin served on the board of directors of Enzymotec Ltd. Mr. Dubin is a certified public accountant and a member of the Maryland Bar. He holds a bachelor’s degree in accounting from the University of Maryland and a J.D. from the National Law Center at George Washington University.
Steve Dubin于2014年1月担任Enzymotec Ltd.公司董事会主席，之前是副主席，于2013年4月被任命为董事。2011年11月，他担任SDA Ventures LLC公司高管，该公司主要针对健康和保健产品公司，从事协助新兴公司和中间市场公司处理包括商业开发、兼并、客户关系、发展策略及公司财政等问题。在SDA Ventures公司工作前，他担任位于纽约、芝加哥旧金山的全球私募股权投资公司Paine & Partners, LLC的资深顾问，主要从事人类和动物食品保健产品行业发现投资机会进行投资。2006年直到2011年2月被Royal DSM N.V。公司收购，他担任Martek Biosciences Corporation公司CEO。之后于2011年2月至2011年10月担任DSM的营养油类产品分部总裁，并于2011年11月至2012年10月担任DSM公司保健产品高级顾问。在1992年加入Martek公司之后他担任多个职位，包括首席财务官、财务主管、秘书、法律总顾问和商业开发高级副总裁等，他于2003年至2006年期间是Martek公司总裁。2000年至2003年，他联合创立并联合管理马里兰州一家天使投资俱乐部（angel-investing club），并于2001年至2002年一段时间担任Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C。公司法律顾问。他目前担任多家私人持有公司董事会成员，包括在NeurExpand Brain Center LLC公司即之前的The Brain Center, LLC公司担任董事会副主席、在MyCell Technologies公司及其子公司Oceans Omega LLC, and Alcresta, Inc.里担任董事会成员。2011年至2012年，他是Scerene Healthcare, Inc.董事会成员。他在马里兰大学（University of Maryland）获得会计学学士学位，在乔治华盛顿大学国家法律中心（National Law Center at George Washington University）获得法学博士学位。他是注册会计师并是Maryland Bar的成员。
Steve Dubin has served as a member of our board of directors since the completion of the merger of resTORbio and Former Adicet in September 2020. Since November 2011 Mr. Dubin has been a Principal in SDA Ventures LLC, a firm focused on assisting emerging growth and middle-market companies, primarily in the health & wellness and nutritional products markets, on matters including corporate development, business acquisition, customer relations, growth strategies and corporate finance. In connection with SDA Ventures LLC, Mr. Dubin acts as a Senior Advisor to Paine Schwartz Partners, LLC, a global private equity investment firm located in New York, and San Mateo, for the purpose of identifying and executing investment opportunities in the global human and animal food and nutritional products industries. From 2006 until its acquisition by Royal DSM N.V. in February 2011 Mr. Dubin served as Chief Executive Officer and a member of the board of directors of Martek Biosciences Corporation. He later served as President of DSM’s Nutritional Lipids Division from February 2011 through October 2011 and as a Senior Advisor to DSM Nutritional Products from November 2011 through October 2012. After joining Martek in 1992 and serving in various management positions, including Chief Financial Officer, Treasurer, Secretary, General Counsel and Senior Vice President, Business Development, he served as President of Martek from 2003 to 2006. Mr. Dubin currently serves as a member of the board of directors of privately held companies Alcresta Therapeutics, Inc., The UCAN Company, Triton Algae Innovations, Ltd. and Phytolon LTD. From January 2014 to January 2018 Mr. Dubin served on the board of directors of Enzymotec Ltd. Mr. Dubin is a certified public accountant and a member of the Maryland Bar. He holds a bachelor’s degree in accounting from the University of Maryland and a J.D. from the National Law Center at George Washington University.

高管简历

中英对照 |  中文 |  英文
Don Healey

Don Healey自2013年4月起担任公司首席科技官。Healey在学术和生物技术环境下的细胞免疫学和免疫调节领域有着25年多的丰富经验。2010年4月加入Opexa，在此之前Healey从2003年到2010年担任免疫学主管，负责为肾癌和艾滋病毒疗法开发新型自体树突细胞疗法。Healey从2001年到2003年担任ML Laboratories, UK 前身是 Cobra Biotherapeutics免疫疗法集团主管，为黑素瘤疗法开发自体树突细胞疗法。Healey从1996年到1998年担任British Society for Immunology议会成员。他之前曾在University of Leicester, UK担任免疫学讲师，在Cambridge University, UK病理学系担任博士后职位，研究自身免疫动物模型的免疫调节，包括Type I Diabetes 和Multiple Sclerosis。Healey持有英国伦敦the Hunterian Institute博士学位；英国Bristol University病理学系理学学士学位。


Don Healey has served as our Chief Technology Officer since October 2020. From February 2017 to October 2020 Dr. Healey served as the Senior Vice President, Operations and Site Head for KBI Biopharma, Inc., a biopharmaceutical contract services organization. From April 2010 to February 2017 Dr. Healey held multiple roles at Opexa Therapeutics, Inc. “Opexa” where he was responsible for all pre-clinical scientific development, closed-system process design and the scaling of Opexa’s autologous T-cell immunotherapy. From March 2001 to April 2010 Dr. Healey held various positions at Argos Therapeutics, Inc. and ML Laboratories, UK, (formerly Cobra Biotherapeutics). Dr. Healey received his Ph.D. from University of London, and holds a B.Sc. in Cellular Pathology from Bristol University.
Don Healey自2013年4月起担任公司首席科技官。Healey在学术和生物技术环境下的细胞免疫学和免疫调节领域有着25年多的丰富经验。2010年4月加入Opexa，在此之前Healey从2003年到2010年担任免疫学主管，负责为肾癌和艾滋病毒疗法开发新型自体树突细胞疗法。Healey从2001年到2003年担任ML Laboratories, UK 前身是 Cobra Biotherapeutics免疫疗法集团主管，为黑素瘤疗法开发自体树突细胞疗法。Healey从1996年到1998年担任British Society for Immunology议会成员。他之前曾在University of Leicester, UK担任免疫学讲师，在Cambridge University, UK病理学系担任博士后职位，研究自身免疫动物模型的免疫调节，包括Type I Diabetes 和Multiple Sclerosis。Healey持有英国伦敦the Hunterian Institute博士学位；英国Bristol University病理学系理学学士学位。
Don Healey has served as our Chief Technology Officer since October 2020. From February 2017 to October 2020 Dr. Healey served as the Senior Vice President, Operations and Site Head for KBI Biopharma, Inc., a biopharmaceutical contract services organization. From April 2010 to February 2017 Dr. Healey held multiple roles at Opexa Therapeutics, Inc. “Opexa” where he was responsible for all pre-clinical scientific development, closed-system process design and the scaling of Opexa’s autologous T-cell immunotherapy. From March 2001 to April 2010 Dr. Healey held various positions at Argos Therapeutics, Inc. and ML Laboratories, UK, (formerly Cobra Biotherapeutics). Dr. Healey received his Ph.D. from University of London, and holds a B.Sc. in Cellular Pathology from Bristol University.
Stewart Abbot

Stewart Abbot曾担任Adicet Bio, Inc.的董事。自2020年9月resTORbio和Former Adicet合并完成以来，担任高级副总裁、首席科学官和首席运营官，此前自2018年7月起担任Former Adicet的高级副总裁、首席科学官和首席运营官。2015年7月至2018年6月，Abbot博士担任Fate Therapeutics, Inc.的翻译研究副总裁兼首席开发官，Fate Therapeutics是一家临床阶段的生物制药公司，开发用于癌症和免疫疾病的细胞免疫疗法。从2007年6月到2015年7月，他在Celgene Cellular Therapeutics担任多个职位，在那里他协助各种细胞治疗研究和开发项目。从2003年10月到2007年6月，他在GE医疗生物科学和GE全球研究担任多个职位。他持有爱丁堡大学(Edinburgh University)的生物科学学士学位、斯特拉斯克莱德大学(University of Strathclyde)的生物医学工程硕士学位和伦敦大学(University of London)的细胞生物学和病理学博士学位。


Stewart Abbot has served as Adicet Bio, Inc. Senior Vice President, Chief Scientific Officer and Chief Operating Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Senior Vice President, Chief Scientific Officer and Chief Operating Officer of Former Adicet since July 2018. From July 2015 to June 2018 Dr. Abbot served as the Vice President of Translational Research and Chief Development Officer of Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders. From June 2007 to July 2015 Dr. Abbot held multiple positions at Celgene Cellular Therapeutics, where he assisted with various cell therapy research and development programs. From October 2003 to June 2007 Dr. Abbot held various positions at GE Healthcare Biosciences and GE Global Research. Dr. Abbot received a B.Sc. in Biological Sciences from Edinburgh University, a M.Sc. in Biomedical Engineering from the University of Strathclyde, and a Ph.D. in Cell Biology and Pathology from the University of London.
Stewart Abbot曾担任Adicet Bio, Inc.的董事。自2020年9月resTORbio和Former Adicet合并完成以来，担任高级副总裁、首席科学官和首席运营官，此前自2018年7月起担任Former Adicet的高级副总裁、首席科学官和首席运营官。2015年7月至2018年6月，Abbot博士担任Fate Therapeutics, Inc.的翻译研究副总裁兼首席开发官，Fate Therapeutics是一家临床阶段的生物制药公司，开发用于癌症和免疫疾病的细胞免疫疗法。从2007年6月到2015年7月，他在Celgene Cellular Therapeutics担任多个职位，在那里他协助各种细胞治疗研究和开发项目。从2003年10月到2007年6月，他在GE医疗生物科学和GE全球研究担任多个职位。他持有爱丁堡大学(Edinburgh University)的生物科学学士学位、斯特拉斯克莱德大学(University of Strathclyde)的生物医学工程硕士学位和伦敦大学(University of London)的细胞生物学和病理学博士学位。
Stewart Abbot has served as Adicet Bio, Inc. Senior Vice President, Chief Scientific Officer and Chief Operating Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Senior Vice President, Chief Scientific Officer and Chief Operating Officer of Former Adicet since July 2018. From July 2015 to June 2018 Dr. Abbot served as the Vice President of Translational Research and Chief Development Officer of Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cellular immunotherapies for cancer and immune disorders. From June 2007 to July 2015 Dr. Abbot held multiple positions at Celgene Cellular Therapeutics, where he assisted with various cell therapy research and development programs. From October 2003 to June 2007 Dr. Abbot held various positions at GE Healthcare Biosciences and GE Global Research. Dr. Abbot received a B.Sc. in Biological Sciences from Edinburgh University, a M.Sc. in Biomedical Engineering from the University of Strathclyde, and a Ph.D. in Cell Biology and Pathology from the University of London.
Francesco Galimi

Francesco Galimi自2020年9月RestorBio与前ADicet合并完成以来一直担任我们的首席医疗官，此前自2019年9月以来一直担任前ADicet的首席医疗官。在Adicet之前，Galimi博士曾在安进公司工作，2015年8月至2019年9月担任全球项目总经理，负责早期开发。任职Amgen公司期间，他曾负责肿瘤学程序组合的跨功能战略和执行，从IND前到后期。从2014年11月到2015年8月，他曾担任Onyx Pharmaceuticals公司的临床开发主管，在那里他曾领导肿瘤临床开发集团。从2011年到2014年，他曾担任the Novartis Research Foundation的基因组学研究所的领导职务，领导肿瘤学项目组合的早期开发。Galimi博士持有都灵大学医学院（University of Torino Medical School）医学肿瘤学专业认证的医学博士学位，以及都灵大学医学院（University of Torino Medical School）的博士学位。


Francesco Galimi has served as our Chief Medical Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Chief Medical Officer of Former Adicet since September 2019. Prior to Adicet, Dr. Galimi worked at Amgen Inc., where he served as Global Program General Manager, Early Development from August 2015 to September 2019. During his tenure at Amgen, he was responsible for the cross-functional strategy and execution of a portfolio of oncology programs, from pre-IND to late-stage. From November 2014 to August 2015 Dr. Galimi was the Head of Clinical Development at Onyx Pharmaceuticals Inc., where he led the Oncology Clinical Development Group. From 2011 to 2014 he served in leadership roles at the Genomics Institute of the Novartis Research Foundation, leading the early development of a portfolio of oncology programs. Dr. Galimi holds a M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. from the University of Torino Medical School.
Francesco Galimi自2020年9月RestorBio与前ADicet合并完成以来一直担任我们的首席医疗官，此前自2019年9月以来一直担任前ADicet的首席医疗官。在Adicet之前，Galimi博士曾在安进公司工作，2015年8月至2019年9月担任全球项目总经理，负责早期开发。任职Amgen公司期间，他曾负责肿瘤学程序组合的跨功能战略和执行，从IND前到后期。从2014年11月到2015年8月，他曾担任Onyx Pharmaceuticals公司的临床开发主管，在那里他曾领导肿瘤临床开发集团。从2011年到2014年，他曾担任the Novartis Research Foundation的基因组学研究所的领导职务，领导肿瘤学项目组合的早期开发。Galimi博士持有都灵大学医学院（University of Torino Medical School）医学肿瘤学专业认证的医学博士学位，以及都灵大学医学院（University of Torino Medical School）的博士学位。
Francesco Galimi has served as our Chief Medical Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Chief Medical Officer of Former Adicet since September 2019. Prior to Adicet, Dr. Galimi worked at Amgen Inc., where he served as Global Program General Manager, Early Development from August 2015 to September 2019. During his tenure at Amgen, he was responsible for the cross-functional strategy and execution of a portfolio of oncology programs, from pre-IND to late-stage. From November 2014 to August 2015 Dr. Galimi was the Head of Clinical Development at Onyx Pharmaceuticals Inc., where he led the Oncology Clinical Development Group. From 2011 to 2014 he served in leadership roles at the Genomics Institute of the Novartis Research Foundation, leading the early development of a portfolio of oncology programs. Dr. Galimi holds a M.D. from the University of Torino Medical School with a specialty certification in Medical Oncology, and a Ph.D. from the University of Torino Medical School.
Carrie Krehlik

Carrie Krehlik自2020年9月RestorBio与前ADicet合并完成以来一直担任我们的首席人力资源官，此前自2017年11月起担任前ADicet的首席人力资源官。2016年7月至2017年11月，Krehlik女士担任Blue Beyond Consulting的顾问。2015年7月至2016年6月，Krehlik女士担任ZsPharma，Inc.人力资源Vice President，该公司是一家开发离子失衡疗法的生物制药公司。2012年12月至2015年3月，Krehlik女士担任InterMune（一家生物制药公司，开发肺病和孤儿纤维化疾病的疗法并将其商业化）的人力资源Vice President。Krehlik女士获得学士学位。Miami University的组织行为学学士学位，以及San Francisco State University的国际商务工商管理硕士学位。


Carrie Krehlik has served as our Chief Human Resource Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Chief Human Resource Officer of Former Adicet since November 2017. From July 2016 to November 2017 Ms. Krehlik served as a consultant to Blue Beyond Consulting. From July 2015 to June 2016 Ms. Krehlik served as the Vice President of Human Resources of ZS Pharma, Inc., a biopharmaceutical company developing therapies for ion imbalances. From December 2012 to March 2015 Ms. Krehlik served as the Vice President of Human Resources at InterMune, a biopharmaceutical company developing and commercializing therapies in pulmonology and orphan fibrotic diseases. Ms. Krehlik received a B.Sc. in Organizational Behavior from Miami University, and an MBA in International Business from San Francisco State University.
Carrie Krehlik自2020年9月RestorBio与前ADicet合并完成以来一直担任我们的首席人力资源官，此前自2017年11月起担任前ADicet的首席人力资源官。2016年7月至2017年11月，Krehlik女士担任Blue Beyond Consulting的顾问。2015年7月至2016年6月，Krehlik女士担任ZsPharma，Inc.人力资源Vice President，该公司是一家开发离子失衡疗法的生物制药公司。2012年12月至2015年3月，Krehlik女士担任InterMune（一家生物制药公司，开发肺病和孤儿纤维化疾病的疗法并将其商业化）的人力资源Vice President。Krehlik女士获得学士学位。Miami University的组织行为学学士学位，以及San Francisco State University的国际商务工商管理硕士学位。
Carrie Krehlik has served as our Chief Human Resource Officer since the completion of the merger of resTORbio and Former Adicet in September 2020 and previously served as Chief Human Resource Officer of Former Adicet since November 2017. From July 2016 to November 2017 Ms. Krehlik served as a consultant to Blue Beyond Consulting. From July 2015 to June 2016 Ms. Krehlik served as the Vice President of Human Resources of ZS Pharma, Inc., a biopharmaceutical company developing therapies for ion imbalances. From December 2012 to March 2015 Ms. Krehlik served as the Vice President of Human Resources at InterMune, a biopharmaceutical company developing and commercializing therapies in pulmonology and orphan fibrotic diseases. Ms. Krehlik received a B.Sc. in Organizational Behavior from Miami University, and an MBA in International Business from San Francisco State University.
Nick Harvey

Nick Harvey自2020年9月RestorBio和前Adicet合并完成以来一直担任我们的首席财务官。此前，他自2018年7月起担任Centrexion Therapeutics Corporation首席财务官，自2018年10月起担任执行Vice President兼财务主管，直至2019年12月，随后担任高级顾问至2020年1月。从2017年6月至2018年6月，他担任私人和公共生命科学公司的独立顾问。在此之前，哈维先生于2006年12月至2017年5月担任Radius Health Inc.的首席财务官。Harvey先生在澳大利亚国立大学（Australian National University）以一级荣誉获得经济学学士学位和法学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。


Nick Harvey has served as our Chief Financial Officer since the completion of the merger of resTORbio and Former Adicet in September 2020. Previously, he served as the Chief Financial Officer since July 2018 and the Executive Vice President and Treasurer since October 2018 of Centrexion Therapeutics Corporation until December 2019 then as Senior Advisor through January 2020. From June 2017 through June 2018 he served as an independent consultant to private and public life science companies. Prior to that, Mr. Harvey served as the Chief Financial Officer of Radius Health Inc. from December 2006 to May 2017. Mr. Harvey received a Bachelor of Economics degree and a Bachelor of Laws degree with first-class honors from the Australian National University and an M.B.A. from the Harvard Business School.
Nick Harvey自2020年9月RestorBio和前Adicet合并完成以来一直担任我们的首席财务官。此前，他自2018年7月起担任Centrexion Therapeutics Corporation首席财务官，自2018年10月起担任执行Vice President兼财务主管，直至2019年12月，随后担任高级顾问至2020年1月。从2017年6月至2018年6月，他担任私人和公共生命科学公司的独立顾问。在此之前，哈维先生于2006年12月至2017年5月担任Radius Health Inc.的首席财务官。Harvey先生在澳大利亚国立大学（Australian National University）以一级荣誉获得经济学学士学位和法学学士学位，并在哈佛商学院（Harvard Business School）获得工商管理硕士学位。
Nick Harvey has served as our Chief Financial Officer since the completion of the merger of resTORbio and Former Adicet in September 2020. Previously, he served as the Chief Financial Officer since July 2018 and the Executive Vice President and Treasurer since October 2018 of Centrexion Therapeutics Corporation until December 2019 then as Senior Advisor through January 2020. From June 2017 through June 2018 he served as an independent consultant to private and public life science companies. Prior to that, Mr. Harvey served as the Chief Financial Officer of Radius Health Inc. from December 2006 to May 2017. Mr. Harvey received a Bachelor of Economics degree and a Bachelor of Laws degree with first-class honors from the Australian National University and an M.B.A. from the Harvard Business School.
Chen Schor

Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。


Chen Schor has served as a member of Karyopharm Therapeutics Inc.'s Board since 2020. Mr. Schor has served as the President, Chief Executive Officer and Director of Adicet Bio, Inc. ("Adicet Bio"), a public biotechnology company, since 2020. He held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and on the board of directors of Alliance for Cancer Gene Therapy, a non for profit organization committed to advancing new cancer cell and gene therapies, since December 2021. Mr. Schor has also served as chair of the board of directors of Koslapp Therapeutics, Inc., a private company, since June 2025. He previously served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant.
Chen Schor，自2016年起担任resTORbio， Inc.的总裁兼首席执行官，直到2020年9月与Adicet Bio合并。在加入resTORbio之前，Schor先生从2014年到2016年担任Synta Pharmaceuticals Corporation的总裁、首席执行官和董事。此前，他曾担任Teva Pharmaceuticals Industries Ltd.的全球品牌业务发展和管道管理副总裁，并在几家新兴的私人和上市公司担任领导职务。在此之前，他是Yozma Venture Capital的合伙人，在那里他领导了多家治疗公司从成立到商业成功的基础和发展。他曾担任resTORbio/Adicet Bio的董事会成员（2016年以来），也曾担任Brainstorm Cell Therapeutics Inc.（上市生物技术公司）的董事会成员和审计委员会成员（2011年至2020年）。他领导了价值超过80亿美元的战略交易，包括GlaxoSmithKline plc、Amgen Inc.、Pfizer、Merck KGaA（共同领导）和Cephalon， Inc.（共同领导）。他持有Tel Aviv大学的生物学学士学位和工商管理硕士学位，以及Haifa大学的经济学和会计学学士学位，他是一名注册会计师。
Chen Schor has served as a member of Karyopharm Therapeutics Inc.'s Board since 2020. Mr. Schor has served as the President, Chief Executive Officer and Director of Adicet Bio, Inc. ("Adicet Bio"), a public biotechnology company, since 2020. He held the role of President and Chief Executive Officer at resTORbio, Inc. ("resTORbio") from 2016 until its merger with Adicet Bio in 2020. Prior to resTORbio, Mr. Schor served as President, Chief Executive Officer and Director of Synta Pharmaceuticals Corporation from 2014 until 2016. Previously, he served as Vice President, Global Branded Business Development and Pipeline Management at Teva Pharmaceuticals Industries Ltd. and held leadership positions at several emerging private and public companies. Before that, Mr. Schor was a Partner at Yozma Venture Capital, where he led the foundation and growth of multiple therapeutic companies from inception to commercial success. Mr. Schor has served on the board of directors of resTORbio/Adicet Bio since 2016 and on the board of directors of Alliance for Cancer Gene Therapy, a non for profit organization committed to advancing new cancer cell and gene therapies, since December 2021. Mr. Schor has also served as chair of the board of directors of Koslapp Therapeutics, Inc., a private company, since June 2025. He previously served on the board of directors and audit committee of Brainstorm Cell Therapeutics Inc., a public biotechnology company, from 2011 until 2020. Mr. Schor holds a B.A. in Biology and an M.B.A. from Tel Aviv University, a B.A. in Economics and Accounting from Haifa University and is a Certified Public Accountant.